Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by gudisgoodon May 12, 2022 4:46pm
171 Views
Post# 34679412

Pretty, pretty GUD...

Pretty, pretty GUD...Always nice to see a strong report. Even better to find out about a new deal on the same day. In addition, the earnings call boosted my confidence in the company. And to end the day on a high note, GUD's trading at an even lower price than yesterday, so the company's likely to buy back more stock at cheaper prices. :)

I'll post more once I get a chance to re-listen and also read the report more carefully.

By the way, Exelon partly transferred over now:

Furthermore, Knight has received the regulatory notification that the
marketing authorization for Exelon® has transfered to Knight’s affiliate in May 2022 in Colombia and will transfer in June 2022 in Brazil
<< Previous
Bullboard Posts
Next >>